U.S. markets open in 3 hours 7 minutes
  • S&P Futures

    4,379.00
    -32.75 (-0.74%)
     
  • Dow Futures

    34,831.00
    -143.00 (-0.41%)
     
  • Nasdaq Futures

    14,863.50
    -174.25 (-1.16%)
     
  • Russell 2000 Futures

    2,223.40
    -14.10 (-0.63%)
     
  • Crude Oil

    73.29
    -0.33 (-0.45%)
     
  • Gold

    1,826.90
    -4.30 (-0.23%)
     
  • Silver

    25.58
    -0.20 (-0.76%)
     
  • EUR/USD

    1.1891
    -0.0006 (-0.05%)
     
  • 10-Yr Bond

    1.2690
    0.0000 (0.00%)
     
  • Vix

    19.13
    +0.82 (+4.48%)
     
  • GBP/USD

    1.3966
    +0.0009 (+0.06%)
     
  • USD/JPY

    109.5980
    +0.1370 (+0.13%)
     
  • BTC-USD

    38,656.91
    -1,833.04 (-4.53%)
     
  • CMC Crypto 200

    919.11
    -11.25 (-1.21%)
     
  • FTSE 100

    7,008.13
    -70.29 (-0.99%)
     
  • Nikkei 225

    27,283.59
    -498.83 (-1.80%)
     

Aptinyx Provides Updates On Mid-Stage NYX-783 Program In PTSD Patients

·1 min read
  • After a Type C meeting with the FDA, Aptinyx Inc (NASDAQ: APTX) has finalized the design of its Phase 2b program for NYX-783 in patients with post-traumatic stress disorder (PTSD).

  • The program will consist of two separate studies to evaluate NYX-783 at two dose levels: 50 mg (Study 1) and 150 mg (Study 2).

  • Both the studies will have 300 patients each.

  • Study 1 will start in Q4 of 2021, while Study 2 will commence in Q1 of 2022.

  • Additionally, Aptinyx disclosed an updated statistical analysis for the recently concluded exploratory Phase 2 study in PTSD after detecting a statistical error made by its contract research organization.

  • “The revised analysis does not impact our conclusions from that study, our confidence in the efficacy and safety profile of NYX-783, or our next steps in its clinical development,” said Norbert Riedel, CEO of the company.

  • After updated statistical analysis, certain study calculations such as CAPS-5 Arousal & Reactivity score and CAPS-5 Negative Cognitions and Mood score for the 50 mg dose vs. placebo had higher p-values than previously reported.

  • But each remains below the significance threshold pre-specified in the statistical analysis plan, it added.

  • Price Action: APTX shares are down 10.60% at $3.12 in the premarket session on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.